insights_auto
Kāpēc uzņēmuma SGIOY akciju cena ir pieaugusi 4,10%?
Atklājiet vairāk iespējuchevron_right
SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
9,13 $
arrow_upward
+4,10%(+0,36) 1 d.
15. okt., 16:00:00 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: SGIOY…
Atvērt
9,53 $
Augsta
9,53 $
Zema
8,95 $
Tirgus kapitalizācija
2,60 trilj.
Vid. apjoms
172,76 tūkst.
Apjoms
120,07 tūkst.
Augstākā 52 ned.
12,00 $
Zemākā 52 ned.
7,83 $
Beta
0,07
Apgrozībā esošās akcijas
1,78 mljrd.
Darbinieku skaits
6 tūkst.
Atvērt
9,53 $
Augsta
9,53 $
Zema
8,95 $
Tirgus kapitalizācija
2,60 trilj.
Vid. apjoms
172,76 tūkst.
Apjoms
120,07 tūkst.
Augstākā 52 ned.
12,00 $
Zemākā 52 ned.
7,83 $
Beta
0,07
Apgrozībā esošās akcijas
1,78 mljrd.
Darbinieku skaits
6 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
ad-hoc-news.de
·
pirms 6 stundām
Jefferies sets JPY 3,900.00 target for Shionogi stock
Profils
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Par “Shionogi 2 ADR Representing 1 Ord Shs”
ĢenerāldirektorsIsao Teshirogi
Darbinieki6,22 tūkst.
Dibināšanas datums1878
Galvenais birojs-
Sektors-
Tīmekļa vietneshionogi.com